GLP-1 weight-loss drugs in Singapore: what's approved, what it costs, and how access actually works

If you live in Singapore and you have been wondering how to legitimately access a GLP-1 weight-loss drug, here is the short version. Two of these medicines are now HSA-approved specifically for weight management, you can only get them through a licensed doctor, you will almost certainly pay for them yourself, and the online sellers offering a cheaper shortcut are exactly what HSA keeps warning people about.

This is an informational guide to how legitimate access actually works here. It is not medical advice, it contains no dosing, and it is not a how-to for getting hold of these drugs without a doctor. Every individual decision about them belongs with a clinician who knows your history.

What these drugs are, in plain English

GLP-1 stands for glucagon-like peptide-1, a hormone your gut releases after you eat. These medicines mimic it, which quietens appetite signals in the brain and slows how fast your stomach empties, so you feel full sooner and stay full longer. The result is less hunger to fight, rather than more willpower to summon.

Two molecules matter here. Semaglutide is a single GLP-1 drug. Tirzepatide is a dual agonist that also hits a second receptor called GIP, and that double action is tied to a larger average effect on weight. Different molecules, not interchangeable brands. For the full mechanism, the trial evidence and the trade-offs around muscle loss and stopping, see our explainer on how GLP-1 drugs for weight loss actually work.

What HSA has actually approved, and the Ozempic trap

This is the distinction that trips almost everyone up, so read it twice.

Wegovy (semaglutide 2.4mg) is HSA-approved specifically for chronic weight management and became available in Singapore in 2025. It is a prescription-only medicine.

Mounjaro (tirzepatide) received HSA approval for weight management in June 2025, as an adjunct to a reduced-calorie diet and more physical activity for adults who meet the BMI and comorbidity criteria. Also prescription-only.

Ozempic (semaglutide) was approved by HSA back in April 2021, but only as a treatment for type 2 diabetes. It was never approved here for weight loss. Using it to slim down in Singapore is off-label.

So when someone says "just get the cheaper Ozempic instead of Wegovy," they are suggesting an off-label use of a diabetes drug, not a swap between two equivalent products. Ozempic and Wegovy are the same molecule licensed for different jobs at different doses. The choice between any of these is a medical decision your doctor makes, not a price comparison you make on your own.

In Singapore, Wegovy and Mounjaro are approved for weight loss. Ozempic is approved for diabetes. That is not a technicality.

What it really costs in SGD

Here is the blunt part. For weight management, these are self-paid. You should budget for the medicine plus consultation and monitoring on top.

Wegovy typically runs roughly SGD 350 to 1,000 a month. The range is driven by your titration dose, the type of clinic, and whether consultation fees are bundled in. The medicine alone often starts around SGD 400 to 500 a month and climbs as you reach maintenance dose.

Mounjaro is commonly quoted around SGD 360 to 400 a month at the lower starting dose, rising to roughly SGD 760 or more a month at higher maintenance doses. Some clinics quote up to around SGD 1,500 per pen depending on dose and programme.

The thing nobody enjoys hearing: for weight loss, none of this is meaningfully subsidised. Wegovy is not covered by MediShield Life or Medisave for weight management, and most private insurance excludes off-label weight-loss use. Medisave may apply only for diabetes treatment in people with a BMI of 27.5 or higher, which is a different indication entirely. Treat this as a long-term out-of-pocket cost, not a one-off.

The legitimate prescription pathway

A real prescription comes from a licensed doctor, a GP, an endocrinologist, or a weight-management clinic, after an actual assessment. That assessment covers your BMI, comorbidities, kidney and liver function, current medications, and mental-health history. Some clinics offer regulated teleconsultations, but the drug still has to be doctor-prescribed.

HSA is clear on this: approved weight-loss medicines are available only from a doctor or pharmacist, because they are potent medications that need medical supervision. A telehealth "quiz" with no genuine clinical review is not the same thing as a proper consultation, and a rubber-stamp script with no real doctor in the loop is the kind of shortcut HSA cautions against.

Who they are for, and who they are not

Singapore and other Asian populations use lower BMI thresholds than Western ones, because metabolic risk shows up at a lower body weight. Drug therapy may be considered at a BMI of 30 or higher, or 27.5 to 29.9 in Asians who also have obesity-related conditions such as hypertension or type 2 diabetes. Some clinics use a BMI of 27.5 or higher, or 25 with comorbidities.

These are clinical tools for people who meet those criteria, screened by a doctor who has ruled out the histories that make the drugs unsafe. They are not a cosmetic top-up for someone a few kilos over their goal weight, and the prescription gate exists precisely to make that judgement properly.

What the evidence shows, and what happens when you stop

The trial numbers are genuinely large, but they come from supervised studies run alongside diet and activity changes.

In STEP 1, a 68-week trial of 1,961 adults with obesity and without diabetes, semaglutide 2.4mg produced mean weight loss of about 14.9% versus 2.4% on placebo. In SURMOUNT-1, tirzepatide achieved mean weight loss of roughly 16% to 22.5% depending on dose, against 2.4% on placebo. SURMOUNT-5, the first direct head-to-head, found tirzepatide produced 20.2% mean weight loss versus 13.7% for semaglutide over 72 weeks.

Now the part the marketing skips. In the STEP 1 extension, a year after stopping semaglutide and the lifestyle programme, participants regained roughly two-thirds of what they had lost, and most of the cardiometabolic gains drifted back towards baseline. These behave like long-term treatments paired with diet and exercise, not a one-off fix.

Side effects and safety

Gastrointestinal effects, nausea, vomiting, diarrhoea and constipation, are common, affecting roughly 50 to 60% of patients early on. They are dose-dependent and usually ease over time.

Serious risks are rarer but real. Acute pancreatitis occurs in about 0.2%, around 2 per 1,000 semaglutide users. Gallbladder events such as gallstones or cholecystitis ran at about 1.6% on semaglutide versus 0.7% on placebo in the STEP trials. HSA is also currently assessing a potential signal for suicidal thoughts and self-harm with GLP-1 receptor agonists. None of these is a reason to panic, but all of them are reasons a prescriber and proper follow-up matter, which is something no online seller provides.

The grey-market danger

This is where the saved dollars turn expensive. HSA warns that weight-loss products sold online are frequently adulterated with undeclared potent or banned ingredients. The most common adulterant is sibutramine, banned in Singapore since 2010 and linked to heart attacks, strokes and irregular heartbeats. You cannot see that in a pen or a pill.

Buying or importing unregistered prescription medicines this way is also illegal in Singapore, and the scale of enforcement is not small. In 2024 alone, HSA seized over 970,000 units of illegal health products and removed more than 7,000 illegal online product listings.

So how do you protect yourself? The legitimate sources are simple to name: a licensed doctor or a registered pharmacist, working from a real clinical assessment. If a "supplier" is a social-media account, an overseas website, or anyone willing to ship you a GLP-1 pen without a prescription, that is the danger, not the deal. A price that looks too good and a doctor who is nowhere in sight are the same warning sign.

Not a shortcut, and not medical advice

If you meet the criteria and you are weighing one of these up, the right next step is a conversation with a licensed Singapore doctor, not a checkout page. A real prescriber screens you, sets up monitoring, and is there when a side effect appears. A grey-market seller does none of that and breaks the law doing it.

This article is informational coverage, not medical advice. It deliberately contains no dosing and no guidance on obtaining these drugs outside the legitimate, doctor-led pathway. GLP-1 medicines are prescription-only and carry real risks. Talk to a doctor or another qualified healthcare professional about whether any of this applies to you before making any decision.

FAQ

Which GLP-1 drugs are approved for weight loss in Singapore?

Wegovy and Mounjaro are HSA-approved for chronic weight management. Ozempic is approved for type 2 diabetes only, not weight loss here.

Can I buy Wegovy online without a prescription?

No. These are prescription-only medicines that must come through a licensed doctor and registered pharmacy. Marketplace listings are a safety and legal red flag.

How much do GLP-1 weight-loss drugs cost in Singapore?

Budget for medicine plus consultation and monitoring. Weight-management use is mostly self-paid, and costs vary by clinic and dose tier. Check current pricing with your doctor.

Is Ozempic the same as Wegovy?

Same molecule, different approved indication and dose in Singapore. Using Ozempic for weight loss is off-label and a medical decision, not a price comparison you make alone.

Who decides if I am eligible?

A licensed clinician assesses BMI, comorbidities and history against HSA criteria. This is informational only, not medical advice, and contains no dosing guidance.

Sources

• Understanding GLP-1 medications in Singapore (HMI Medical)
• Mounjaro in Singapore: what you need to know in 2025 (The SIRE)
• Ozempic in Singapore: uses, limitations and alternatives (Health365)
• Dubious weight loss products sold online can harm your health (HSA)
• HSA Annual Summary 2024 (HSA press release)
• Wegovy in Singapore pricing guide (Of Noah)
• Tirzepatide / Mounjaro Singapore guide (Nexus Aesthetics)
• Are GLP-1 agonists covered by insurance or Medisave in Singapore? (Advantage Medical Group)
• GLP-1 weight-loss medications in Singapore: who qualifies and how to get started (Of Noah)
• GLP-1 side effects overview (GoodRx)
• HSA assessing potential risk of suicidal thoughts and self-harm with GLP-1 RA (HSA safety alert)
• Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1, NEJM 2021)
• Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1, Eli Lilly, 2022)
• Tirzepatide vs semaglutide head-to-head (SURMOUNT-5, ACC, 2025)
• Weight regain after withdrawal of semaglutide (STEP 1 extension, 2022)
• GLP-1 receptor agonists for obesity: eligibility across 99 countries (Lancet Diabetes & Endocrinology, 2025)